Intensity Therapeutics Appoints New Director, Loses One
Ticker: INTS · Form: 8-K · Filed: May 24, 2024 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, management-change
TL;DR
Intensity Therapeutics swapped a director, bringing in Epstein and losing Roth.
AI Summary
Intensity Therapeutics, Inc. announced on May 21, 2024, a change in its board of directors. Dr. Jonathan M. Roth, a director since 2021, has resigned. The company has also appointed Dr. David M. Epstein as a new director, effective immediately. Dr. Epstein brings extensive experience in the pharmaceutical and biotechnology sectors.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty about strategic direction and leadership stability.
Key Players & Entities
- Intensity Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Resigned Director
- Dr. David M. Epstein (person) — Appointed Director
- May 21, 2024 (date) — Effective date of changes
FAQ
When did Dr. Jonathan M. Roth join the board of Intensity Therapeutics?
Dr. Jonathan M. Roth had been a director since 2021.
What is the effective date of Dr. David M. Epstein's appointment?
Dr. David M. Epstein's appointment as a director is effective immediately as of May 21, 2024.
What is the primary business of Intensity Therapeutics?
Intensity Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
In which state is Intensity Therapeutics incorporated?
Intensity Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address of Intensity Therapeutics?
The principal executive offices are located at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-24 16:00:38
Key Financial Figures
- $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
Filing Documents
- intensity-20240521.htm (8-K) — 24KB
- 0001567264-24-000021.txt ( ) — 152KB
- intensity-20240521.xsd (EX-101.SCH) — 2KB
- intensity-20240521_lab.xml (EX-101.LAB) — 23KB
- intensity-20240521_pre.xml (EX-101.PRE) — 13KB
- intensity-20240521_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 24, 2024 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer 2